Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS, Lilly Reach Agreement To Co-Develop Erbitux Follow-On

This article was originally published in The Pink Sheet Daily

Executive Summary

During its fourth-quarter 2009 earnings call, Bristol also urged investors to show patience with disappointing sales of Onglyza.

You may also be interested in...



Deals Of The Week: Idenix/Janssen, Genentech/Afraxis, Immunomedics/Algeta

With Super Bowl mania rampant, what are the chances of the biopharmaceutical industry’s equivalent: a mega-merger within big pharma? A Wall Street analyst downplays the likelihood of another Pfizer/Wyeth-like pairing, but raises the possibility that industry will see a mid-sized deal intended to mimic the success of the Sanofi/Genzyme merger.

Blood Clot Risk Causes Lilly, Bristol To Halt Enrollment In Erbitux Follow-On Trial

Safety concern occurs about one year after the two companies resolved rights dispute over antibody arising from Lilly/ImClone merger.

Blood Clot Risk Causes Lilly, Bristol To Halt Enrollment In Erbitux Follow-On Trial

Safety concern occurs about one year after the two companies resolved rights dispute over antibody arising from Lilly/ImClone merger.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel